Carbomax — Carboplatin
Carboplatin was developed specifically to give oncologists a better-tolerated alternative to Cisplatin — same platinum-based mechanism, meaningfully lower kidney and hearing toxicity — which is why hospitals treating ovarian and lung cancer very often stock both platinum agents side by side, selecting between them based on individual patient tolerability and kidney function rather than treating them as interchangeable.
- Approved indications: Ovarian cancer, lung cancer
- Mechanism: An alkylating agent that inhibits DNA, RNA, and protein synthesis in cancer cells, halting replication and triggering programmed cell death
- Clinical positioning: The preferred platinum agent when nephrotoxicity or ototoxicity risk from Cisplatin is a specific concern for a given patient
- Order pattern: Frequently co-ordered alongside Cisplatin by hospitals maintaining flexibility to select the appropriate platinum agent per patient — a bundling opportunity worth flagging at quote stage
Key Product Facts
450 mg
Strength
1 Vial (S) Of 15 ml
Pack Size
Carboplatin
Active Ingredient
Oncology
Category
Enquire Now for Pricing
Price
Carboplatin was developed specifically to give oncologists a better-tolerated alternative to Cisplatin — same platinum-based mechanism, meaningfully lower kidney and hearing toxicity — which is why hospitals treating ovarian and lung cancer very often stock both platinum agents side by side, selecting between them based on individual patient tolerability and kidney function rather than treating them as interchangeable.
- Approved indications: Ovarian cancer, lung cancer
- Mechanism: An alkylating agent that inhibits DNA, RNA, and protein synthesis in cancer cells, halting replication and triggering programmed cell death
- Clinical positioning: The preferred platinum agent when nephrotoxicity or ototoxicity risk from Cisplatin is a specific concern for a given patient
- Order pattern: Frequently co-ordered alongside Cisplatin by hospitals maintaining flexibility to select the appropriate platinum agent per patient — a bundling opportunity worth flagging at quote stage
- Myelosuppression: The dose-limiting toxicity for Carboplatin — regular blood count monitoring is essential, with particular attention to platelet counts
- Hypersensitivity: Allergic reactions can occur, and risk increases with repeated treatment cycles — patients require monitoring, especially from the second cycle onward
- Renal caution: While less nephrotoxic than Cisplatin, kidney function is still monitored given the drug's clearance pathway
- Fertility: May cause temporary or permanent fertility reduction in both men and women — contraception required during treatment and for 6 months after final dose
- Drug interaction caution: Should not be combined with Cisplatin or other anticancer drugs without specific medical guidance, and should not be given alongside recent live vaccines
| Document |
Included |
| Certificate of Analysis (COA) |
Standard |
| Certificate of Origin (COO) |
Standard |
| MSDS |
Standard |
Stock status: In stock for export | Quote turnaround: 24 hours
- Logistics: Standard export logistics, room-temperature stable, no cold chain required
- Coverage: Global export markets
- Bundling option: Can be co-shipped with Cisplatin to reduce total logistics and documentation cost for hospitals stocking both
What is Carboplatin used for?
Treats ovarian and lung cancer, often combined with other chemotherapy agents.
Get Carboplatin price from a GMP-compliant Indian supplier — how?
Send required quantity and destination for competitive bulk pricing.
How is it different from Cisplatin?
It causes significantly less kidney and hearing toxicity, making it the preferred choice for patients where those risks are a concern.
Can it be combined with Cisplatin?
No, combining the two platinum agents isn't recommended — hospitals typically choose one based on patient factors, though many stock both.
Who supplies Carboplatin from India?
WHO-GMP certified manufacturer with full export documentation and competitive bulk pricing.
